Epredia: Technologies for Cancer Diagnostics

Epredia is a global leader in precision cancer diagnostics that specializes in anatomical pathology. Established in 2019 following PHC Holdings’ acquisition of Thermo Fisher Scientific’s Anatomical Pathology business, Epredia offers a wide range of solutions that enhance workflow efficiency from sample collection to analysis, contributing to faster, more accurate and precise diagnoses.

The range of products that Epredia offers include laboratory instruments, microscope slides, staining reagents and systems for the digitalization of pathological samples. Epredia’s solutions are supported by important brands for instance Shandon, Microm, Menzel, Gläser and Richard-Allan Scientific, which continuously change the anatomical pathology market. Epredia’s mission is to improve results for patients providing updated technologies, which enable pathologists to carry out accurate cancer diagnostics.

Furthermore, Epredia places a strong emphasis on innovation and customer support, working closely with laboratories and research institutes to provide tailored solutions that meet specific diagnostic and research needs. The operational leasing of Epredia technologies allows laboratories to access cutting-edge solutions without initial investments, with more predictable costs, continuous updates, and tax benefits that support their economic sustainability.